TGFB1 and cancer: Suppression of CDCP1 cleavage by TA may be preferable to that induced by TGFβ and glucocorticoids since these agents block Plasminogen activation by upregulating Plasminogen Activator Inhibitor-1 (PAI-1) and activate transcriptional programs that may not be beneficial in the cancer setting.